129 related articles for article (PubMed ID: 37131688)
21. A hierarchical self-attention-guided deep learning framework to predict breast cancer response to chemotherapy using pre-treatment tumor biopsies.
Saednia K; Tran WT; Sadeghi-Naini A
Med Phys; 2023 Dec; 50(12):7852-7864. PubMed ID: 37403567
[TBL] [Abstract][Full Text] [Related]
22. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
23. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
[TBL] [Abstract][Full Text] [Related]
24. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
25. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
Wang RX; Ji P; Gong Y; Shao ZM; Chen S
Front Immunol; 2022; 13():940635. PubMed ID: 36341391
[TBL] [Abstract][Full Text] [Related]
26. [Prediction of Response to Neoadjuvant Chemotherapy for Breast Cancer Based on Histomorphology Analysis of Needle Biopsy Images].
Xu CY; Xie JW; Yang CX; Jiang YN; Zhang ZH; Xu J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):279-285. PubMed ID: 33829703
[TBL] [Abstract][Full Text] [Related]
27. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
van den Ende NS; Nguyen AH; Jager A; Kok M; Debets R; van Deurzen CHM
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769287
[TBL] [Abstract][Full Text] [Related]
28. The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.
Kimura Y; Masumoto N; Kanou A; Fukui K; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
Surg Oncol; 2022 May; 41():101725. PubMed ID: 35189516
[TBL] [Abstract][Full Text] [Related]
29. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
30. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Dong X; Liu C; Yuan J; Wang S; Ding N; Li Y; Wu Y; Xiao Z
Breast Care (Basel); 2021 Aug; 16(4):328-334. PubMed ID: 34602938
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
33. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
[TBL] [Abstract][Full Text] [Related]
34. Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Jung YY; Hyun CL; Jin MS; Park IA; Chung YR; Shim B; Lee KH; Ryu HS
J Breast Cancer; 2016 Sep; 19(3):261-267. PubMed ID: 27721875
[TBL] [Abstract][Full Text] [Related]
35. Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy.
Liu J; Xu Y; Yu M; Liu Z; Xu Y; Ma G; Zhou W; Kong P; Ling L; Wang S; Pan H; Zhao Y
Cancer Manag Res; 2019; 11():10791-10800. PubMed ID: 31920388
[TBL] [Abstract][Full Text] [Related]
36. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W; Munari E; Horlings HM; Mulder L; Bogina G; Sanders J; Liu YH; van den Belt-Dusebout AW; Tessier L; Balkenhol M; Stegeman M; Hoven J; Wesseling J; van der Laak J; Lips EH; Ciompi F
Breast Cancer Res; 2023 Nov; 25(1):142. PubMed ID: 37957667
[TBL] [Abstract][Full Text] [Related]
37. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Malhaire C; Selhane F; Saint-Martin MJ; Cockenpot V; Akl P; Laas E; Bellesoeur A; Ala Eddine C; Bereby-Kahane M; Manceau J; Sebbag-Sfez D; Pierga JY; Reyal F; Vincent-Salomon A; Brisse H; Frouin F
Eur Radiol; 2023 Nov; 33(11):8142-8154. PubMed ID: 37318605
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
[TBL] [Abstract][Full Text] [Related]
39. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization.
Gomez-Macias GS; Molinar-Flores G; Lopez-Garcia CA; Santuario-Facio S; Decanini-Arcaute H; Valero-Elizondo J; Treviño-Alvarado V; Ortiz-Lopez R; Dono A; Esteban-Zubero E; Alatorre-Jimenez MA; Garza CV; Peña-Curiel O; Cardona-Huerta S
Oncol Lett; 2020 Nov; 20(5):140. PubMed ID: 32934708
[TBL] [Abstract][Full Text] [Related]
40. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
